Monitor subsequent patient cohort enrollment and data readouts from the ongoing Phase 1/2A trial for AL001. No immediate catalyst; the filing is a routine scientific presentation disclosure.
Price Chart
Executive Summary
Alzamend Neuro filed an 8-K to disclose a presentation at the ISMRT Conference on September 29, 2026, by the principal investigator of its Phase 1/2A clinical trial for AL001, a novel organic lithium salt. The presentation reported brain pharmacokinetics imaging results at 7T MRI, showing trends for slightly higher lithium brain concentration and AUC after AL001 compared to inorganic Li2CO3, but differences were not statistically significant due to the small sample size. This is a routine scientific disclosure with no new financial or regulatory catalyst.
Key Facts
- Phase 1/2A clinical trial of AL001 (lithium salicylate/L-proline co-crystal) in 30 participants (6 each: healthy, bipolar, major depression, Alzheimer, PTSD).
- Brain PK imaging at 7T showed a trend for slightly higher Li concentration after AL001 (geometric mean 4020.64 ng/g, 64% CV) vs Li2CO3 (3476.94 ng/g, 57% CV).
- Non-compartment PK modeling showed a trend for slightly higher AUC after AL001 (geometric mean 62230 h*ng/g, 26% CV) vs Li2CO3 (59715 h*ng/g, 25% CV).
- Differences between AL001 and Li2CO3 were not statistically significant, in line with the small sample size.
- The observed trends in the healthy cohort generate hypotheses to be tested in subsequent patient cohorts (bipolar, major depression, Alzheimer and PTSD).
Financial Impact
No financial data or material impact not reported in this filing.
Risk Factors
- AL001 has not demonstrated statistically significant superiority over standard Li2CO3 in this small Phase 1/2A study.
- Clinical-stage biotech with no approved products; regulatory or commercial milestones are distant.
- Small sample size limits current data reliability.
- Pre-revenue company with high cash burn risk; no revenue or financial guidance reported.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001214659-26-012132 |
| Exhibit: ex99_1.htm | 0001214659-26-012132 |
| Document: 0001214659-26-012132-index-headers.html | 0001214659-26-012132 |
| Document: 0001214659-26-012132-index.html | 0001214659-26-012132 |
| Document: 0001214659-26-012132.txt | 0001214659-26-012132 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 28d ago | 8-K | $1.82 $1.13 | ▼ −37.91% | ▼ −38.63% | $1.13 (−37.91%) |
Aug 4, 2026 11w ago | 3 | $1.43 $1.70 | ▲ +18.88% | ▲ +19.48% | $1.13 (−20.98%) |
Feb 26, 2026 34w ago | DEFA14A | $2.01 $1.05 | ▼ −47.76% | ▼ −40.20% | $1.13 (−43.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers